Cambridge Trust’s Exelixis EXEL Stock Holding History

Cambridge Trust’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-425	Closed	-$8K	–	999
2021 Q4	$8K	Buy	+425	New	+$8.13K	﹤0.01%	849

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cambridge Trust's EXEL Position: Q1 2022 in Review

Cambridge Trust sold out of Exelixis (EXEL) in Q1 2022, closing a stake of 425 shares — an estimated $8K sold.

Cambridge Trust first reported a position in EXEL in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 363 funds tracked by Wall St. Rank hold EXEL as of Q1 2022.

Cambridge Trust reported no remaining Exelixis position as of Q1 2022 after selling out during the quarter.
Cambridge Trust sold 425 Exelixis shares in Q1 2022, an estimated $8K.
Cambridge Trust first reported a position in Exelixis in Q4 2021 and held it in 1 quarter.
Cambridge Trust's Exelixis position peaked at $8K in Q4 2021.
363 funds tracked by Wall St. Rank held Exelixis as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.